Creo Medical Group PLC (AIM:CREO), the therapeutic device company, saw revenues in its first half lift by over 15% as it continued to feel the benefit of its endotherapy division, a trading company released on Thursday revealed.
Sales in the six months to 30 June 2023 jumped year-on-year to £15.7 million from £13.6 million, driven by 12% growth in endotherapy consumable revenues which reached £14.3 million.
Kamaptive revenue was flat, in comparison to 2022, at £500,000 and Creo’s core technology brought in £900,000 – also equal to the year prior.
Craig Gulliford, chief executive officer of Creo, commented: "Creo has made considerable strides across all areas of the business over the past six months, not only in terms of attracting the necessary funding to provide us with a clear path towards break-even but also in terms of the rapid pace of adoption and recognition that the company is now achieving globally.
“This has been reflected in the significantly improved performance in both our core technology revenues and our number of confirmed users.”
Shares in Creo Medical are up more than 1.3% on Thursday, having opened at around 34p.